explore -WSS

explore

author：knowledge 2025-10-02 22:57:01 - browse：43

Multiple syringes in a vial -- Pharma coverage from STAT — Adobe

Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members of this already vulnerable group will wind up facing what physician Andrew Schuman recently called “a tragedy happening in slow motion” — an ongoing, nationwide shortage of critical oncology drugs that routinely save or extend the lives of children and adults.

Speaking at a March 22 Senate hearing on drug shortages, Schuman, a head and neck surgeon at the U.S. Department of Veterans Affairs, described the agonizing decisions that doctors must make when critical medicines are in short supply. “Should our limited vials go to an older woman who was just diagnosed with lung cancer? To a young man who had already been successfully taking it for his testicular cancer? Or a baby with neuroblastoma?” he asked. “As a doctor who has devoted my life to fighting cancer, it is hard to express how horrible it is to face this kind of tragedy.”

The dilemmas caused by cancer drug shortages are unfortunately nothing new. In the past decade alone, eight of the 10 drugs most commonly used to treat acute lymphoblastic leukemia, the most common kind of childhood cancer type of leukemia, have been temporarily unavailable. The problem has been getting worse: Nationwide shortages of critical drugs increased nearly 30% in 2022, soaring to their highest level in nearly five years, according to a report released by the Senate Homeland Security and Governmental Affairs Committee for the hearing. Oncology drugs currently in short supply include methotrexate, which treats breast and soft tissue cancers; cisplatin, which treats testicular, ovarian, bladder, head and neck, lung, and cervical cancers; fluorouracil, which treats skin cancer; Pluvicto, for prostate cancer; and the injectable bacillus Calmette-Guérin, for bladder cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Telehealth options flood the market as retailers push virtual care

WSS

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Teach medical students about patients with intellectual disabilities

In diabetes hearing, Sanders takes on a new foe: food makers

Spinal cord stimulation reduces pain in amputees, study finds

Chemotherapy shortages won’t get better under Biden’s latest plan

Readout Newsletter: New research from Sanofi, Regeneron, etc.

leisure time

explore

focus

The high cost of giving birth even with insurance

Patients' immediate access to test results puts radiologists in a bind

How to save PrEP access — and even expand it

Eli Lilly to pay $200M for Beam’s stake in gene

Sports medicine is finally prioritizing gender equality

Why sickle cell disease is getting the first CRISPR treatment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

CMS should re

Medicare proposal to cover medical devices draws a mixed reaction

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

hotspot

Pregnancy discrimination could be enabled by AI

Chemotherapy shortages won’t get better under Biden’s latest plan

CDC recommends rationing of RSV shot due to shortages

Maker of FluMist seeks to allow at

FDA needs staff influx to meet gene therapy needs, Marks says

STAT letters to the editor on burnt

knowledge

hotspot

focus

hotspot